T1	intervention 98 107	tamoxifen
T2	intervention 112 123	fenretinide
T3	eligibility 372 417	premenopausal women at risk for breast cancer
T4	No-of-participants 469 472	235
T5	intervention 541 550	tamoxifen
T6	intervention 559 570	fenretinide
T8	control 597 604	placebo
T9	duration 609 616	2 years
T12	intervention-value 963 966	13%
T13	intervention-value 968 970	2%
T14	intervention-value 972 975	20%
T15	control-value 981 983	1%
T16	outcome-Measure 1158 1170	IGF-I levels
T17	adverse-effect 1408 1428	optic nerve ischemia
T18	adverse-effect 1437 1459	deep venous thrombosis
T19	outcome 1493 1578	no difference in menopausal symptoms, endometrial thickness, polyps, or ovarian cysts
T20	outcome 1613 1627	breast cancers
T21	control-value 1610 1612	24
T7	outcome 987 999	IGF-I levels
